title: What is the optimal medical management of ischaemic heart failure?
abstract: Ischaemic heart disease is probably the most important cause of heart failure. All patients with heart failure may benefit from treatment designed to retard progressive ventricular dysfunction and arrhythmias. Patients with heart failure due to ischaemic heart disease may also, theoretically, benefit from treatments designed to relieve ischaemia and prevent coronary occlusion and from revascularisation. However, there is little evidence to show that effective treatments, such as angiotensin converting enzyme (ACE) inhibitors and beta-blockers, exert different effects in patients with heart failure with or without coronary disease. Moreover, there is no evidence that treatment directed specifically at myocardial ischaemia, whether or not symptomatic, or coronary disease alters outcome in patients with heart failure. Some agents, such as aspirin, designed to reduce the risk of coronary occlusion appear ineffective or harmful in patients with heart failure. There is no evidence, yet, that revascularisation improves prognosis in patients with heart failure, even in patients who are demonstrated to have extensive myocardial hibernation. On current evidence, revascularisation should be reserved for the relief of angina. Large-scale, randomised controlled trials are currently underway investigating the role of specific treatments targeted at coronary syndromes in patients who have heart failure. The CHRISTMAS study is investigating the effects of carvedilol in a large cohort of patients with and without hibernating myocardium. The WATCH study is comparing the efficacy of aspirin, clopidogrel and warfarin. The HEART-UK study is assessing the effect of revascularisation on mortality in patients with heart failure and myocardial hibernation. Smaller scale studies are currently assessing the safety and efficacy of statin therapy in patients with heart failure. Only when the results of these and other studies are known will it be possible to come to firm conclusions about whether patients with heart failure and coronary disease should be treated differently from other patients with heart failure due to left ventricular systolic dysfunction.
authors.affiliation: Department of Cardiology, Castle Hill Hospital and Hull Royal Infirmary, Kingston upon Hull, UK.
authors.forename: J G
authors.initials: JG
authors.lastname: Cleland
authors.forename: J
authors.initials: J
authors.lastname: John
authors.forename: J
authors.initials: J
authors.lastname: Dhawan
authors.forename: A
authors.initials: A
authors.lastname: Clark
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D004077:Digoxin / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D017202:Myocardial Ischemia / Q000188:drug therapy*; D009204:Myocardial Revascularization; D009566:Nitrates / Q000627:therapeutic use; D018579:Patient Selection; D016540:Smoking Cessation; D013148:Spironolactone / Q000627:therapeutic use; D015912:Thrombolytic Therapy
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D002316:Cardiotonic Agents; D004232:Diuretics; D000960:Hypolipidemic Agents; D009566:Nitrates; D013148:Spironolactone; D004077:Digoxin